Subcutaneous pembrolizumab with platinum-based chemotherapy for untreated metastatic non-small-cell lung cancer [TSID12213] Medicine Not selected 16 June 2025 Oral cabotegravir with rilpivirine for ...

The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

What this means in practice Obe‑cel is not required to be funded in the NHS in England to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults. It should not be used ...

2.1 Obecabtagene autoleucel (obe‑cel; Aucatzyl, Autolus Limited) is indicated for 'the treatment of adult patients (aged 18 years and older) with relapsed or refractory B-cell precursor acute ...

NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...

01 July 2025 via Zoom Draft Agenda The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to ...

In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

Notice of Appeal Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] NICE has received 1 appeal, that falls within one or more of the two strictly ...

This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...

Capacity impact The capacity impact of this topic will have been realised while the treatment has been in the Cancer Drugs Fund. So, no significant change in capacity is anticipated. Localities can ...

Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...